🎬 ON DEMAND VIDEO
When Beta Cell Specification Fails: A Knockout Village Reveals Lineage Rewiring in Human Islet Development Dingyu Liu PhD Candidate • June 30 2026
📺 Now available on demand ▶ Watch the Full Talk
💬 Key Quote
“It's really the village that gives us the scale and also single-cell resolution to reveal this other side of monogenic diabetes. It's not just about the loss of beta cells — it's also about what the cells become.” — Dingyu Liu, PhD Candidate
🔬 Foundational Insights as They Apply to T1D
The standard story of monogenic diabetes is a story of arrest: a mutation in a transcription factor essential to beta cell development — PDX1, PAX6, RFX6, and roughly a dozen others — stalls the developmental program, beta cells fail to form in adequate numbers, and diabetes results. That account has been built gene by gene, over decades, largely from individual mouse knockouts studied one at a time — PDX1 loss producing near-total pancreatic agenesis, RFX6 loss producing endocrine cells that fail to turn on insulin or glucagon. What that gene-by-gene approach has never been able to answer is what those failed cells actually become, and whether there is a shared logic across different monogenic diabetes genes rather than 15 separate, disconnected stories.
Liu’s PhD work, from the Huangfu lab at Memorial Sloan Kettering, answers that question using a strategy she calls the “knockout village.” Rather than differentiating each CRISPR knockout line through the roughly 20-day stem-cell-to-islet protocol one at a time — an approach that is slow and vulnerable to batch and clonal variation that can obscure real phenotypes — the lab generated 76 CRISPR-engineered human embryonic stem cell lines (36 genotypes) targeting 30 diabetes- and islet-agenesis-associated genes, gave each line a unique heritable genetic barcode, and then pooled 79 of those clones into a single shared differentiation dish. The cells were profiled by single-cell RNA sequencing at five time points spanning pluripotency through early SC-islet stage, and demultiplexed by barcode afterward to recover the phenotype of each individual knockout — all cultured, differentiated, and sequenced under identical conditions.
The village recapitulated the expected phenotype: most knockout genotypes showed a reduced fraction of beta cells relative to wild type, with RFX6 among the most severely affected — consistent with decades of prior mouse and human data. But tracing the data back to earlier time points revealed something the gene-by-gene literature could not show directly: failing cells were not simply dying or stalling. They were being actively redirected toward alternative lineages, and which alternative lineage depended on which gene was lost — FOXA2 knockout cells were biased toward liver fate, GSC (goosecoid) knockout cells toward stromal fate. These redirections held up in individual (non-pooled) differentiations, confirming the effects are cell-autonomous rather than artifacts of pooled culture.
The most striking convergence, and the center of the talk, involved three genotypes — RFX6, PDX1, and PAX6 knockouts — which all showed the same paired signature: severe loss of beta cells alongside a corresponding gain of enterochromaffin (EC)-like cells, an endocrine cell type not normally considered part of the islet. This was reproducible in individual differentiations and, critically, was not just an in vitro artifact: reanalysis of a 20-year-old human RFX6-mutant patient sample (which had not originally been checked for EC markers) and of Rfx6-knockout mouse embryonic pancreas (E15.5) both showed the same pattern — CHGA-positive endocrine cells that had lost insulin, glucagon, and somatostatin expression, with the mouse data additionally showing a significant increase in the EC markers TPH1 and SLC18A1. That cross-species, cross-system convergence gave the team confidence that the EC-like fate is a genuine pathological cell state, not a cell-culture accident — and, intriguingly, the EC-specific gene program the team identified showed even stronger neuronal-feature enrichment than other endocrine gene programs, echoed by cross-referencing against a human fetal single-cell atlas spanning 15 organs (gestational weeks 11–13).
Using non-negative matrix factorization to define 36 gene expression programs across the dataset, and the SCENIC+ computational method to infer transcription factor regulators from single-cell multiome data, Liu’s team found that beta cell and EC gene programs are governed by largely distinct transcription factor sets — and identified ISL1 as a candidate downstream repressor of the EC fate, based on its expression being down in EC-high knockouts and negatively correlated with EC:beta ratio across genotypes, together with prior human genetic reports linking ISL1 mutations to early-onset diabetes. Overexpressing ISL1 in wild-type cells, ISL1-knockout cells, and — critically — in PDX1-knockout and PAX6-knockout cells was sufficient to repress the EC gene program across all of them, showing ISL1 acts downstream of at least two other monogenic diabetes genes to guard against the EC fate. ISL1 overexpression also reactivated the beta cell program in wild-type and ISL1-knockout cells, but notably not in the PDX1 or PAX6 knockouts — indicating those two genes have additional beta-cell-promoting roles beyond simply working through ISL1.
🎯 Core Premise
Using a pooled, barcoded "knockout village" of 79 CRISPR-engineered human stem cell lines spanning 30 monogenic-diabetes-associated genes, profiled by single-cell RNA sequencing across five time points of islet differentiation, Liu and colleagues show that loss of beta cell specification regulators does not simply block beta cell formation — it actively redirects developing cells toward alternative, gene-dependent fates. Three genotypes in particular (RFX6, PDX1, PAX6) converge on the same non-canonical outcome: a gain of enterochromaffin (EC)-like cells with serotonergic and neuronal features, a pattern independently confirmed in human patient tissue and mouse knockout embryos. ISL1 was computationally predicted and experimentally validated as a downstream repressor of this EC fate, acting under both PDX1 and PAX6. The result reframes monogenic diabetes pathology as a story about cell fate redirection, not merely beta cell insufficiency — and the knockout village itself is a reusable, scalable platform for studying many developmental regulators simultaneously with single-cell resolution.
🌟 Why This Talk Matters to T1D Scientists and Clinicians
For scientists: The knockout village is the methodological advance the field is likely to adopt widely. hPSC differentiation studies have long been limited by batch effects and clonal variability that make it hard to compare phenotypes across knockout lines run in separate experiments. By barcoding every line and pooling them into a single shared differentiation, Liu’s approach recovers high-confidence, directly comparable phenotypes for 30 genes across five developmental time points in one experiment — a platform any lab studying hPSC developmental genetics could, in principle, adapt. The finding that developmental transcription factors function as much by suppressing alternative fates as by promoting the target fate is a general principle now demonstrated at scale in human cells, and the convergence of three independent monogenic diabetes genotypes on the same EC-like exit fate — validated computationally, then experimentally with ISL1 — is a concrete proof that this atlas-scale approach can generate specific, testable mechanistic hypotheses about understudied regulators.
For clinicians: Monogenic diabetes is frequently misdiagnosed as type 1 or type 2 disease, in part because the underlying developmental mechanisms have been understood gene by gene and incompletely. This work suggests that for at least three of the most severe monogenic forms (RFX6, PDX1, PAX6-associated disease), the pathology may not be simple beta cell insufficiency but active misdirection of progenitors into a non-canonical, serotonergic, neuron-like cell state whose functional consequences in the human islet are still unknown. The stage-specific failure map the village produces — showing that different genes fail at different points in the roughly 20-day differentiation program — is also directly relevant to the growing number of SC-derived islet cell therapy programs now in clinical trials for T1D, since those same differentiation protocols can, off-target, generate EC-like cells instead of the intended beta cells. Identifying ISL1 as a factor that can redirect cells away from the EC fate and back toward beta cell identity — including downstream of PDX1 and PAX6 loss — is a concrete, actionable lead for improving those protocols.
3️⃣ Big Takeaways
Losing a beta cell transcription factor doesn’t just erase beta cells — it reroutes the cells somewhere else, and where they end up depends on which gene was lost. Profiling 79 pooled, barcoded knockout lines across 30 genes and five time points, the team found that most knockouts reduce beta cell yield, as expected, but also actively increase alternative-fate populations — liver-like cells in FOXA2 knockouts, stromal-like cells in GSC knockouts — and these effects held up when tested in individual, non-pooled differentiations, ruling out pooled-culture artifacts as the explanation.
Three of the most clinically severe monogenic diabetes genes — RFX6, PDX1, and PAX6 — converge on the same non-canonical outcome: a gain of enterochromaffin (EC)-like cells. This EC-like population expresses serotonin pathway genes (TPH1, SLC18A1) and shows unusually strong neuronal gene-program features even relative to other endocrine cell types, and the same pattern was independently confirmed in a re-examined human RFX6-mutant patient sample and in Rfx6-knockout mouse embryos (E15.5) — evidence that this is a genuine pathological cell state relevant in vivo, not an artifact specific to stem-cell culture.
ISL1 was computationally predicted and then experimentally validated as a downstream guardian of beta cell identity against the EC fate, acting under both PDX1 and PAX6. Using gene program analysis (NMF) and transcription-factor inference (SCENIC+) across the whole knockout village dataset, the team identified ISL1 as a candidate repressor of the EC program; overexpressing ISL1 suppressed the EC gene program in wild-type, ISL1-knockout, PDX1-knockout, and PAX6-knockout cells alike, though it only restored the beta cell program in the first two — indicating PDX1 and PAX6 have beta-cell-promoting functions beyond what ISL1 alone can rescue.
❓ Key Questions from the Discussion
How late into differentiation does ISL1 overexpression rescue the beta cell fate, and does the effect persist? Katarina Zorc asked how far into maturation the EC-to-beta-cell recovery with ISL1 overexpression had been tested. Liu explained the results shown were from early-stage differentiation, but preliminary data extending culture out to roughly 10 days of additional maturation suggest the EC-suppressing effect of ISL1 overexpression is maintained across multiple time points, with longer maturation time courses still ongoing.
Do ISL1-overexpressing cells show improved hormone specificity (reduced polyhormonality) and actual insulin-secretory function? A questioner asked whether ISL1 overexpression improves polyhormonality or was tested by glucose-stimulated insulin secretion (GSIS). Liu said GSIS testing hasn’t been done yet but is planned, and noted that assessing true polyhormonality is complicated in this in vitro system because nearly all endocrine cells in the differentiation carry some baseline insulin expression alongside glucagon or somatostatin — making single-cell sequencing after ISL1 overexpression a better path to clarifying exactly which cells become what.
Could the large proportion of wild-type cells in the pooled village be rescuing knockout cells’ phenotypes, masking a stronger true effect? Diego Matías asked whether co-culturing knockouts with a majority of wild-type cells (roughly 70% wild type to 30% knockout in the village) could create a favorable local environment that partially rescues the knockout phenotype, potentially underestimating the true effect size. Liu agreed this is plausible — that ratio was chosen specifically to mitigate knockout-knockout interactions confounding results — but noted the defects observed were nonetheless substantial, and that most reported phenotypes were independently confirmed in individual (unpooled) differentiations.
Is there direct in vivo evidence of increased EC-like cells in human monogenic diabetes patients, beyond the reanalyzed RFX6 sample? Ed Sanchez asked whether there’s evidence for a higher fraction of EC-like cells in monogenic diabetes patient pancreata versus non-diabetic controls. Liu acknowledged that direct human evidence is currently limited to the single reanalyzed RFX6-mutant patient sample, since monogenic diabetes is rare and pancreatic biopsy is not standard clinical practice; supporting in vivo evidence otherwise comes from the Rfx6-knockout mouse model, with gene expression data from the other knockout mouse models not yet available but of active interest to the group.
Do beta cells arising in the non-canonical (EC) state show altered cell-cell communication within the islet? Nina Ostrer (referred to as “Nina Itis” in the transcript) asked whether non-canonical-state cells show reduced or altered signaling with other islet cell types. Liu noted the pooled-culture design makes it difficult to control or attribute exactly which cell types are signaling to which within the village, so this question hasn’t yet been directly addressed.
How reproducible are cell-fate outcomes across independent clones of the same knockout genotype? Juan Alvarez asked about village-to-village reproducibility of cell type allocation across different clonal lines of the same knockout. Liu reported that for most genotypes, two independent clonal lines were tested and showed generally reproducible cell type composition across differentiation stages.
Does NKX6-1 mark EC cells as well as beta cells, and could that inform strategies to generate C-peptide-positive, NKX6-1-negative cells? Christian Schutz asked about a slide suggesting NKX6-1 positively regulates EC cells as well as beta cells, and whether it might therefore be beneficial to generate C-peptide-positive but NKX6-1-negative cells. Liu called it a great and still-unresolved question: NKX6-1 is expressed in EC cells, and its expression increases in ISL1 knockouts — suggesting NKX6-1 marks both cell states rather than being beta-cell-specific — but the group does not yet have genetic evidence clarifying how NKX6-1 mechanistically shapes EC versus beta cell development or function.
🔗 3 TSS Talks That Connect With This One
Ask the Expert: Dario Gerace, PhD — Harvard University Dr. Gerace’s work engineering immune-evasive stem cell-derived islet cells (Melton lab) situates today’s developmental biology inside the broader SC-islet cell therapy program that is now in clinical trials for T1D. Because the differentiation protocols used to make clinical SC-islets can, off-target, generate non-canonical populations like the EC-like cells Liu’s team describes, understanding the clinical stakes of getting beta cell specification right — rather than just efficient — makes Liu’s mechanistic findings directly actionable.
Ask the Expert: Lorenzo Pasquali, PhD — Pompeu Fabra University Dr. Pasquali’s work on beta cell noncoding regulatory function provides the gene-regulatory-network framework — how transcription factors bind regulatory elements to control identity programs — that underlies everything in Liu’s talk. Watching this alongside today’s talk clarifies what it actually means, mechanistically, for a transcription factor like PDX1 or ISL1 to be “guarding” one cell fate against another.
Ask the Expert: Ruth Elgamal, PhD Candidate — UCSD Elgamal’s discussion of the integrated pancreatic islet reference map from the Human Pancreas Analysis Program (HPAP) supplies the single-cell classification vocabulary and marker-gene frameworks — SC-β, SC-α, SC-δ, and non-canonical populations like SC-EC — that are central to interpreting Liu’s single-cell RNA-seq results and the novel EC-like cell state she describes.
🔔 Subscribe to The Sugar Science newsletter to get the latest T1D research drops straight to your inbox.